Table 1.
Demographic and clinical characteristics of the study participants. G20: ALS patients with diagnosis in 2020; G18: ALS patients with diagnosis in 2018. N: number; SD: standard deviation; IR: interquartile range; ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; FVC: forced vital capacity; BMI: body mass index. Values are reported as mean (standard deviation, SD) or median (interquartile range, IQR).
| G20 (n = 34) | G18 (n = 31) | p-Value | |
|---|---|---|---|
| Age (years) at onset (SD) | 66.23 (9.90) | 62.83 (13.43) | >0.05 |
| Male/Female (%) | 19 (56%)/ 15 (44%) |
15 (48%)/ 16 (52%) |
>0.05 |
| Months from onset to diagnosis (IQR) | 9.00 (6.24–12.76) |
10.50 (6.00–12.00) |
>0.05 |
| Phenotype (%): - spinal - bulbar |
24 (71%) 10 (29%) |
19 (61%) 12 (39%) |
>0.05 |
| Cognition (%): - normal - impaired |
21 (62%) 13 (38%) |
23 (74%) 8 (26%) |
>0.05 |
| Gene mutations (%): - negative - C9Orf72 |
31 (91%) 3 (9%) |
29 (94%) 2 (6%) |
>0.05 |
| ALSFRS-R at baseline (SD) | 38.51 (5.34) |
39.03 (5.35) |
>0.05 |
| FVC% at baseline (SD) | 75.41 (22.27) | 84.00 (16.63) | >0.05 |
| BMI at baseline (SD) | 23.90 (4.48) | 25.35 (5.36) | >0.05 |